Co-Diagnostics (CODX) Set to Post Earnings on Tuesday

Co-Diagnostics (NASDAQ:CODX) is projected to issue its Q3 2026 results after the market closes on Tuesday, November 10th. Analysts expect Co-Diagnostics to post earnings of ($1.25) per share and revenue of $0.17 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:30 PM ET.

Co-Diagnostics (NASDAQ:CODX) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.46) earnings per share for the quarter, topping the consensus estimate of ($3.00) by $1.54. Co-Diagnostics had a negative return on equity of 210.99% and a negative net margin of 6,531.77%. The firm had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.13 million.

Co-Diagnostics Price Performance

NASDAQ:CODX opened at $0.26 on Monday. The firm’s fifty day moving average price is $0.89 and its 200 day moving average price is $2.15. Co-Diagnostics has a 1-year low of $0.24 and a 1-year high of $13.54. The firm has a market cap of $2.44 million, a price-to-earnings ratio of -0.02 and a beta of 3.16.

Analysts Set New Price Targets

A number of equities analysts have commented on CODX shares. Maxim Group upgraded shares of Co-Diagnostics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 18th. Weiss Ratings raised shares of Co-Diagnostics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, October 27th. Finally, Wall Street Zen upgraded shares of Co-Diagnostics from a “sell” rating to a “hold” rating in a research note on Saturday, August 22nd. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Co-Diagnostics presently has an average rating of “Hold” and an average target price of $45.00.

About Co-Diagnostics

Co-Diagnostics, Inc is a molecular diagnostics company that develops and commercializes diagnostic tests and laboratory technologies. Based in Salt Lake City, Utah, the company focuses on assays that detect genetic material from infectious diseases and other medical conditions.

The company’s core technology is its CoPrimer platform, which is designed to support the development of molecular tests using specialized primer technology. Products associated with the platform include the Logix Smart line of real-time polymerase chain reaction (PCR) assays, covering applications such as respiratory and other infectious diseases.